Treatment options for invasive fungal infections (Q36484945)

14 August 2017

1 reference

title

Treatment options for invasive fungal infections (English)

1 reference

invasive fungal infections

14 August 2017

main subject

1 reference

based on heuristic

inferred from title

author

Elizabeth Dodds Ashley

series ordinal

1

object named as

Elizabeth S Dodds Ashley

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 June 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

26

1 reference

14 August 2017

issue

6 Pt 2

1 reference

14 August 2017

page(s)

55S-60S

1 reference

Amphotericin B: time for a new "gold standard".

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

PubMed Central: creating an Aladdin's cave of ideas

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Cyclophosphamide metabolism is affected by azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.6PART2.55S

10.1592/PHCO.26.6PART2.55S

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference